“…FCM is preferred over immunohistochemical analysis since it allows for the examination of more markers and their intensity determination7,8. The expression of CD4, CD56, and CD123 in the absence of T-cell, B-cell, or myeloid markers defines BPDCN4-8. The correct diagnosis implies an appropriate panel of antibodies; in contrast, insufficient knowledge on this entity and inadequate immunophenotypic investigation can lead to the misdiagnosis of a different leukemia8.…”